Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14138740 | 0.80 | AR (0.43) | AR | |
| SCHEMBL13106347 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL3976812 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL29863815 | 0.78 | AR (0.51) | ARPGRNR3C2 | |
| SCHEMBL973688 | 0.75 | AR (0.49) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1930255 | 0.75 | AR (0.53) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1642132 | 0.75 | AR (0.49) | ARPGRNR3C2NR3C1 | |
| SCHEMBL220882 | 0.75 | AR (0.53) | AR | |
| SCHEMBL20517275 | 0.75 | HTR2A (0.37) | AR | |
| SCHEMBL1643385 | 0.75 | AR (0.39) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-01 | — | — | US | disclosed |
| CN-115023267-A | Spirocyclic androgen receptor protein degrading agents | 密歇根大学董事会 | 2022-09-06 | — | — | CN | disclosed |
| EP-4031241-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | The Regents Of The University Of Michigan (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| EP-1722790-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | Bristol-Myers Squibb Company (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1718626-A1 | SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD | Brystol-Myers Squibb Company (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005089118-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005086735-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087232-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20050197367-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005077925-A1 | SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | NR3C2, AR, NR4A3 | AR 2/4885PGR 119/4885NR3C2 1/4885 |
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | AR, ESRRA, NR5A1 | AR 1/4885PGR 63/4885NR3C2 28/4885 |
| US-20050197367-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | AR, NR5A1, ESRRA | AR 1/4885PGR 75/4885NR3C2 25/4885 |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, NR5A1, ESRRA | AR 1/4885PGR 201/4885NR3C2 17/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | AR 1/4885PGR 120/4885NR3C2 21/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | AR 1/4885PGR 40/4885NR3C2 14/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | AR 1/4885PGR 40/4885NR3C2 14/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | AR 1/4885PGR 40/4885NR3C2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.